Skip to main content

Mirum Pharmaceuticals, Inc.

corporate_fare Company Profile

Mirum Pharmaceuticals, Inc.

MIRM·NASDAQ·Life Sciences·CIK 0001759425

We are a biopharmaceutical company focused on treating rare diseases. We have three approved medicines: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI® (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor. It is approved for cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S., the European Union (EU), and various other countries. Livmarli is also approved for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) in the U.S., Canada, and Japan, and for the treatment of PFIC in the EU. We market Livmarli in the U.S., Canada, and certain European countries through our commercial team and have license and distribution agreements for other countries. We are also conducting the EXPAND study to add indications for Livmarli for cholestatic pruritus due to other rare conditions. In August 2023, we acquired assets from Travere Therapeutics, Inc. related to the development, manufacture, and commercialization of chenodiol and Cholbam (also known as Kolbam). The U.S. Food and Drug Administration (FDA) approved Cholbam in March 2015 as the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder (PBD-ZSD). Chenodiol is the standard of care for cerebrotendinous xanthomatosis (CTX) in the U.S. and was commercialized as Chenodal. We submitted a New Drug Application (NDA) for chenodiol for CTX in 2024 and received FDA approval for the treatment of adults with CTX in February 2025.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for MIRM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for MIRM spans 8-K, 10-Q.

Recent high-impact activity:

  • Mirum's Brelovitug Hits AZURE-4 Primary Endpoint, Completing Phase 3 Package for BLA
  • Brelovitug Hits Primary Endpoint in Second Phase 3, Completing Registrational Package
  • Mirum 10-Q: Q3 Sales $185.7M, $898.1M Nine-Month Loss on Bluejay IPR&D Charge
  • Mirum Q3 Sales $185.7M, Lifts 2026 Product Sales Guidance to $715-720M
  • Mirum Lifts 2026 Sales Guidance to $715-720M After Q3 Revenue Jump to $185.7M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$521.31M
Net Income
-$23.36M
Diluted EPS
-$0.47
Op. Cash Flow
$55.83M
Free Cash Flow
$54.87M
Gross Profit
$421.07M
Operating Income
-$22.14M
Cash & Equivalents
$296.68M
Debt / Equity
0.00×
Net Margin
-4.5%
Shares Outstanding
51.9M sh
Source: 10-K · filed 2026-02-25 · accession 0001759425-26-000013

Short Interest & Short Volume

11.84 days to cover

FINRA reported short interest of 6,523,716 shares in MIRM as of the October 30, 2026 settlement, a 2.1% decrease from the prior period — about 11.8 days to cover at its recent average daily volume. On November 20, 2026, 64.9% of MIRM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,523,716 shares as of October 30, 2026
Change vs prior period▼ 2.1%
Days to cover11.84 at avg daily volume of 551,116
Daily short volume (FINRA facilities)64.9% of 303,328 shares on November 20, 2026
5-day average short volume55.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with M →
$96.13
52-week range · as of 2026-11-10 $63.23 – $130
Market cap
$6.28B
Volume
1.1M (1.6× avg)
3-mo avg 647.8K
Live data · 2026-11-21 05:38 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MIRM - Latest Insights

MIRM
Nov 10, 2026, 7:41 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $93.18
Real-time Price: $96.13 info
Change: +$2.95 (+3%) info
Market Cap: $6.276B info
MIRM
Nov 10, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
9
Price at Filing: $93.18
Real-time Price: $96.13 info
Change: +$2.95 (+3%) info
Market Cap: $6.276B info
MIRM
Nov 03, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $96.13 info
Change: +$9.10 (+10%) info
Market Cap: $6.276B info
MIRM
Nov 03, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $96.13 info
Change: +$9.10 (+10%) info
Market Cap: $6.276B info
MIRM
Nov 03, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $87.03
Real-time Price: $96.13 info
Change: +$9.10 (+10%) info
Market Cap: $6.276B info
MIRM
Oct 26, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $80.15
Real-time Price: $96.13 info
Change: +$15.98 (+20%) info
Market Cap: $6.276B info
MIRM
Oct 13, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $86.20
Real-time Price: $96.13 info
Change: +$9.93 (+12%) info
Market Cap: $6.276B info
MIRM
Oct 12, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $92.00
Real-time Price: $96.13 info
Change: +$4.13 (+4%) info
Market Cap: $6.276B info
MIRM
Sep 28, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $91.99
Real-time Price: $96.13 info
Change: +$4.14 (+5%) info
Market Cap: $6.276B info
MIRM
Sep 28, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $91.99
Real-time Price: $96.13 info
Change: +$4.14 (+5%) info
Market Cap: $6.276B info
MIRM
Sep 25, 2026, 7:00 PM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $91.00
Real-time Price: $96.13 info
Change: +$5.13 (+6%) info
Market Cap: $6.276B info
MIRM
Aug 05, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $97.54
Real-time Price: $96.13 info
Change: -$1.41 (-1%) info
Market Cap: $6.276B info
MIRM
May 18, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $95.49
Real-time Price: $96.13 info
Change: +$0.640 (+0.67%) info
Market Cap: $6.276B info
MIRM
May 13, 2026, 12:17 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $104.50
Real-time Price: $96.13 info
Change: -$8.37 (-8%) info
Market Cap: $6.276B info
MIRM
May 12, 2026, 5:17 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $104.50
Real-time Price: $96.13 info
Change: -$8.37 (-8%) info
Market Cap: $6.276B info
MIRM
May 06, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $110.00
Real-time Price: $96.13 info
Change: -$13.87 (-13%) info
Market Cap: $6.276B info
MIRM
May 06, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $110.00
Real-time Price: $96.13 info
Change: -$13.87 (-13%) info
Market Cap: $6.276B info
MIRM
May 06, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $110.08
Real-time Price: $96.13 info
Change: -$13.95 (-13%) info
Market Cap: $6.276B info
MIRM
May 04, 2026, 11:41 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $109.72
Real-time Price: $96.13 info
Change: -$13.59 (-12%) info
Market Cap: $6.276B info
MIRM
May 04, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $100.20
Real-time Price: $96.13 info
Change: -$4.07 (-4%) info
Market Cap: $6.276B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets